Rezultati pretraživanja
  1. 17. kol 2019.

    Faculty profile up! With a link to our website! Come check us out and spread the word - we are looking for undergrads, grad students and post-docs to help figure out why cells fail and design the next generation of !

  2. 17. lis 2019.

    We’re thrilled to debut ArsenalBio! Grateful to , and all our investors. Honored to advance our scientific founders’ trailblazing work. Committed to bring curative immune to patients.

  3. In my book I write, "Umbilical cord stem cell therapy is the ideal treatment for a wide array of chronic pain disorders and diseases." Umbilical cord blood is invaluable to many . Why? Find out in this fascinating article from .

  4. prije 12 sati

    TreeFrog Therapeutics () brings in senior profiles to drive the advent of high-quality & affordable allogenic -

  5. 's Dan Weiss, , & I critically discuss the current status of for diseases & efforts to rein in businesses offering interventions:

    Prikaži ovu nit
  6. 4. velj

    ICON continues its research in through various & . Find out more

  7. 3. velj

    I submitted my abstract to ! We show a silk-elastin protein can deliver , , , or even locally to deliver a 'one-two punch' at tumors.

  8. 3. velj

    . has entered an agreement to acquire , a technology-focused CDMO, adding capabilities and technologies for the development and manufacture of autologous and allogeneic .

  9. 31. sij

    Sadik Kassim, PhD, Chief Technology Officer at , will present “Bioprocessing Opportunities for the Next Generation of Immuno-Oncology Targeted Cell Therapies” at our in .

  10. 30. sij

    “Our goal in life is to turn cell therapy into the first line of treatment,” said our CEO, Paul Wotton, while speaking to about that will be off-the-shelf and easy for to access. Read more via here

  11. 30. sij

    Dr Daniel Chen, IGM Biosciences will debate against Dr Carl June, , on Bispecifics vs Cell Therapies on February 26th during the IO360° conference in New York City. Learn more at

  12. Wow, a ruling in FAVOR of ? Maybe the judge has benefited from ® or ® or hopes to from ®. Biotech leading those patented & established therapies is

  13. 29. sij

    MIT spin-out company signed a deal with to co-develop the FlowfectTM system, a scalable process that reportedly yields billions of engineered cells in minutes.

  14. 29. sij
  15. 16. sij

    We are excited to announce that we have entered into a definitive under which we will acquire to strengthen our position in T . Read more here:

  16. 12. pro 2019.

    Folks I've posted our slides here: A wholly novel method to restore CAR-T activity in patients relapsing from CD19-directed cell therapy

  17. 11. pro 2019.
  18. Here's a new collection of reviews on - covering regulatory T cells for immune disorders, gamma delta T cells for cancer and HSCs for blood disorders. Apologies for any issues with free access - these have been fixed

  19. Interested in ? Here's a new collection of freely accessible reviews - covering regulatory T cells for immune disorders, gamma delta T cells for cancer and engineered haematopoietic stem cells for blood disorders

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.